Ionetix

About

About Ionetix

Medical isotopes, and the accelerators that make them.

street-signage-1

Ionetix leverages its proprietary cyclotron and accelerator expertise to produce a growing portfolio of critical medical isotopes for targeted alpha therapy and diagnostic imaging.

For therapeutics, Ionetix is focused on producing high-purity, alpha-emitting therapeutic isotopes, including actinium-225 and astatine-211; the Company ships Ac-225 globally and At-211 in North America.

For diagnostics, Ionetix manufactures Positron Emission Tomography (PET) radiopharmaceuticals through its network of FDA-approved sites close to the point of care. These agents are used in imaging for a variety of medical conditions, including cardiology, oncology and neurology.

Ionetix is also exploring additional applications for its particle accelerator technology beyond isotope production.

The Facts

  • 2009

    Incorporated

    Delaware.

  • ~75

    People

    Full-time employees.

  • 2

    Michigan sites

    Corporate headquarters and cyclotron manufacturing, and therapeutic isotope production.

  • 9

    FDA PET sites

    A production network spanning the United States.

What does Ionetix do?

Ionetix leverages its proprietary cyclotron and accelerator expertise to produce a growing portfolio of critical medical isotopes for targeted alpha therapy and diagnostic imaging.

Where is Ionetix located?

Ionetix is headquartered at 3130 Sovereign Drive, Lansing, Michigan, USA, and operates a network of nine FDA-approved PET production sites across the United States.

When was Ionetix founded?

Ionetix was incorporated in Delaware in 2009.

Which isotopes does Ionetix produce?

Actinium-225 and astatine-211 for targeted alpha therapy, and nitrogen-13, fluorine-18 and gallium-68 for diagnostic imaging.

Investor information.